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Summary This study was undertaken to investigate the pathways involved in the interleukin 2 (IL-2)-driven
growth of tumour-infiltrating lymphocytes (TILs). For this purpose, TIL lines and freshly isolated TILs
obtained from 16 patients with solid cancer (three melanoma, seven primary colorectal carcinoma, four hepatic
metastases from colorectal cancer and two lung cancer) were evaluated for (a) expression of IL-2 receptor
(IL-2R) both at the RNA level and on the cell surface by flow cytometric analysis and (b) their proliferative
activity in response to IL-2 and the role of IL-2R subunits in the IL-2-driven TIL growth. Northern blot
analysis showed that TILs express a strong message for both the p55 and the p75 IL-2R. Accordingly, flow
cytometric analysis demonstrated that TILs bear both IL-2R chains. TILs cultured in vitro in the presence of
rIL-2 were able to proliferate in response to different concentrations of this cytokine. Monoclonal antibodies
(MAbs) specifically recognising the p55 and p75 IL-2R chains (anti-Tac and TU27 respectively) exhibited a
marked inhibitory effect on IL-2-driven growth when added individually or in appropriate combinations. Our
results demonstrated that TILs are equipped with a fully functional IL-2 receptor system, thus suggesting the
involvement of this structure in the activation and expansion of TILs following immunotherapy with IL-2.
Tumour-infiltrating lymphocytes (TILs) display potent anti-
tumour activity (Itoh et al., 1986; Muul et al., 1987;
Rosenberg et al., 1988; Kradin et al., 1989; Rosenberg, 1991).
They might control tumour growth by mediating a wide
spectrum of functional activities including cytotoxicity,
cytokine release, helper and suppressor activities, or a com-
bination of these effects (Itoh et al., 1986; Topalian et al.,
1989; Balch et al., 1990; Kim et al., 1990; Pandolfi et al.,
1991). Human TILs have been expanded from a variety of
solid tumours, primarily in the presence of interleukin 2
(IL-2) and to a lesser extent of interleukin 4 (IL-4).
Nowadays, data regarding the ability of TILs to control
tumour growth have been extensively provided, but the
mechanisms accounting for their proliferation in vitro and
possibly in vivo have not been definitively investigated
(Kawakami et al., 1988; Yagita et al., 1989; Shimuzu et al.,
1991).
IL-2 is a cytokine that plays a key role in T-cell prolifera-
tion (Robb, 1984; Smith, 1988), mediating several functions
by means of binding to specific surface IL-2 receptors (IL-
2Rs) (Tsudo et al., 1989, Waldmann, 1991). Three forms of
IL-2Rs are distinguishable on the basis of the affinity for
their ligand: low-, intermediate- and high-affinity IL-2Rs.
Different combinations of three distinct chains, the ax (p55), p
(p75) and (p64) chains, form the three different classes of
IL-2 receptors (Wang & Smith, 1987; Waldmann, 1991;
Hatakeyama et al., 1989a; Tsudo et al., 1990; Takeshita et
al., 1992; Arima et al., 1992; Voss et al., 1993; Noguchi et al.,
1993). While low-affinity receptors contain IL-2Roa, but not
IL-2RP or IL-2Ry, intermediate-affinity IL-2Rs contain the P-
and 'y-chains, but not the ax-chain. High-affinity receptors are
formed from all three subunits. Monoclonal antibodies
(MAbs) specifically recognising p55 and p75 IL-2Rs have
been produced (Uchiyama et al., 1981; Takeshita et al., 1989;
Tsudo et al., 1989), thus allowing the characterisation of
IL-2Rs on different cell types. The effects of IL-2 on cells
equipped with specific receptors are likely to be mediated by
the p75 IL-2Rs rather than by the p55 chain (Robb &
Greene, 1987; Wang & Smith, 1987).
This study was undertaken to analyse the mechanisms
through which IL-2 drives the growth of TILs in vitro. To
this purpose, TIL lines and freshly isolated TILs obtained
from 16 patients with solid cancer were evaluated for (a) the
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expression of IL-2Rs both at mRNA level and on the cell-
surface membrane and (b) the role of these receptors in the
IL-2-driven TIL growth.
Materials and methods
TIL isolation andexpansion
TIL lines were derived from surgical specimens of 12 patients
with solid tumours (five primary colorectal carcinoma, four
hepatic metastases from colorectal cancer and three primary
melanoma). Tumour samples were washed with RPMI-1640
(Gibco, Paisley, UK) medium to minimise possible peripheral
blood lymphocyte (PBL) contamination in the TIL prepara-
tions and were successively cut into 1 mm fragments. The
fragments were cultured in RPMI-1640 containing 10% fetal
calf serum (FCS) (ICN, Oxnard, CA, USA), 100 U ml-'
recombinant IL-2 (kindly supplied by Biogen Corp., Cam-
bridge, MA, USA), 50 U ml-' penicillin, 50 tLg mlh' strep-
tomycin, 50 tgmlh- gentamicin and 200 ngml' fungizone.
In nine of the 12 patients (nos. 1 to 9 in Table I), TIL
cultures were expanded in the presence of IL-2 for 2 days
and restimulated with phytohaemaoagglutinin (PHA) (0.1 jig ml- ) and irradiated feeders (normal PBL). Twelve hours
after restimulation, medium was almost completely removed
from the wells and was replaced with RPMI-1640 containing
IL-2 alone. All studies were performed 14-18 days after
restimulation. In three of the 12 patients (nos. 10 to 12 in
Table I), TIL lines were derived in the presence of IL-2
(100 U ml-') alone. Six TIL lines were tested for their func-
tional ability to kill NK-sensitive (the in vitro-cultured K-562
line) or NK-resistant (Raji) targets and autologous tumour
cells. Tumour cells were obtained following digestion of
tumour specimens and rosetting of cell suspension, as des-
cribed below. After removal of sheep red blood cell (SRBC)-
rosetting T lymphocytes, the remaining cells were almost
completely represented by tumour cells with a few con-
taminants (macrophages, B cells and fibroblasts). When used
as targets, tumour cells were thawed and their viability was
determined by means of the trypan blue exclusion test.
Preparations with more than 80% viable cells were used as
targets. Cytotoxic assays were performed using proliferating
lymphocytes as effector cells. Briefly, 1 x 106 targets (thawed
tumour cells and cultured K-562 cells) were labelled for 2 h
at 37°C in 5% carbon dioxide with 100jiCi of [5"Cr]sodium
chromate (CEA IRE Sorin, Biomedica, Saluggia, Italy) and
were thoroughly washed before use. Target cells (105ml-')
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Table I Phenotypic analysis and cytotoxic function oftumour-infiltrating lymphocyte
cell lines
Cytotoxicit/a
Autologous Surface phenotype (%)
Patient no. K-562 RAJI tumour CD3 CD4 CD8 CD56
1 55.9 23 26 98 41 58 28
2 76 46.7 31.0 99 58 41 9
3 ND ND ND 98 54 34 1
4 44 42.2 4.4 99 40 62 10
5 ND ND ND 99 59 35 18
6 ND ND ND 99 22 75 ND
7 65 25 48 99 16 83 27
8 ND ND ND 98 75 18 21
9 56 28 41 99 10 85 13
10 29 30 3 89 21 61 15
11 88 36 ND 93 29 66 4
12 55 38 ND 99 36 63 28
aPer cent specific lysis at the 20:1 effector/target ratio.
ND, not determined.
were suspended in each V-shaped plate well (Titertek; ICN,
Oxnard, CA, USA), graded concentrations of effector cells
were added to wells in triplicate at different effector/target
ratios (5:1, 10:1, 20:1, 40:1) and then incubated at 37°C in
5% carbon dioxide for 4 h. After this incubation period,
supernatants were harvested and counted in a gamma-
counter. The mean value of triplicate assays was used to
calculate the percentage of cytotoxicity according to the fol-
lowing formula:
c.p.m. effector cells - c.p.m. spontaneous release x 100
c.p.m. maximum release - c.p.m. spontaneous release
Spontaneous release was always less than 8% from the K-562
and tumour targets. The results reported refer to a 20:1
effector/target ratio. Six out of nine TIL lines tested dis-
played a significant killing of autologous tumour cells (Table
I), while the killing of NK-sensitive targets at the 20:1
effector/target ratio was variable.
In four patients (Table II; two subjects with lung cancer
and two patients with colorectal cancer), freshly isolated
TILs were obtained following digestion of tumour specimens
in RPMI-1640 medium supplemented with 10% FCS, 0.1%
collagenase type IV (Sigma, St Louis, MO, USA), 0.002%
DNAse type 1 (Sigma) and 0.01% hyaluronidase type V
(Sigma) for 1-2 h at 37°C. Cell suspensions containing both
TILs and tumour cells were washed and passed through a
surgical gauze. TILs were purified by rosetting the cell
suspension with neuroaminidase (Sigma)-treated SRBCs fol-
lowed by repeated Ficoll/Hypaque gradient separations as
previously described in detail (Trentin et al., 1990a). Cell
populations obtained using this procedure comprised TILs
and tumour cell populations. More than 90% of cells were
viable as judged by the trypan blue exclusion test. The
phenotypic analysis of freshly isolated TILs is reported in
Table II.
Northern blot analysis
Total cellular RNA was extracted from 107 TIL lines after
lysis with 4 M guanidine isothiocyanate and by centrifugation
through a 5.7 M caesium chloride gradient. A 10gg aliquot
of each sample was denatured at 65°C for 10 min in an
electrophoresis buffer (20mM morpholinopropane sulphonic
acid, 6.5% formaldehyde, 50% formamide, 0.05 mg ml-'
Table II Phenotypic analysis of freshly isolated tumour-infiltrating
lymphocytes from four patients
Surface phenotype (%)
Patient no. CD3 CD4 CD8 CD56
1 95 26 66 7
2 94 53 41 18
3 91 34 68 10
4 90 48 38 21
ethidium bromide), size fractionated by electrophoresing on
1.0% agarose gel containing 6.5% formaldehyde then trans-
ferred to nylon filters. Filters were dried, soaked in 0.05 M
sodium hydroxide for 5 min, prehybridised at 42°C for 6 h
with a prehybridisation solution (50% formamide, 5 x Den-
hardt's solution, 0.1% SDS, 100 mgml-' denatured salmon
sperm DNA) and hybridised at 42°C for 15 h in the same
solution containing the 32P random-priming labelled probe.
The messages for p55 IL-2R were detected as 3.5 kb and
1.5 kb size mRNA by hybridisation with purified 0.9 kb
cDNA fragment from the IL-2R cDNA kindly provided by I.
Stamenkovic (Charlestown, MA, USA). The transcripts for
the p75 IL-2R were detected as 4.0 kb size mRNA by hyb-
ridisation with the cDNA fragment subcloned into pUC19
vector kindly provided by M. Hatakeyama (Osaka, Japan)
(Hatakeyama et al., 1989a). After hybridisation, filters were
washed twice in 2 x SSC with 0.5% SDS and twice in
0.1 x SSC with 0.1% SDS at 65°C. Filters were exposed for
1-5 days at - 80°C to Kodak X-OMAT XAR-5 films.
Rehybridisation of the filters with another probe was per-
formed after washing the membrane in 20mM Tris-HCI,
0.1% SDS, for 2h at 85C.
Monoclonal antibodies andflow cytometry analysis
TILs were studied for the expression of cell-surface antigens
with direct two-colour analysis using FITC-conjugated and
phycoerythrin-conjugated MAbs using flow cytometric anal-
ysis (FACScan, Becton Dickinson) as previously described
(Trentin et al., 1990b). To characterise the expression of
IL-2R on TILs, before performing the phenotypical study,
cells were washed in 40 mM citrate containing 140 mM
sodium chloride (pH4) to remove cell-bound IL-2, as des-
cribed in detail in Zambello et al. (1990). The following
MAbs were used: anti-CD25 (anti-Tac) MAb, which recog-
nises the p55 IL-2R and blocks IL-2 binding to this subunit,
was a gift from T. Uchiyama (Kyoto, Japan) (Uchiyama et
al., 1981); TU27 MAb was a gift from K. Sugamura (Senday,
Japan) and J. Hamuro (Kawasaki, Japan); it recognises the
p75 chain of IL-2R. Controls for flow cytometry analysis
were performed using isotype control antibodies.
The expression of IL-2 receptors on TILs was also inves-
tigated by evaluating the binding of phycoerythrin-con-
jugated IL-2 (PE-IL-2, R & D Systems, Minneapolis) on the
cell surface using a flow cytometer. Briefly, 10gil of PE-IL-2
(10 igml-') was added to 106 cells and the mixture was
incubated on ice for 60min. Cells were then washed twice
and resuspended in 0.2 ml of PBS for flow cytometric
analysis. As control for the FACS analysis, cells were
incubated with a control IgG and avidin PE. The lym-
phocytes were analysed as indicated below. Blocking
experiments were carried out by pretreating the cells for 1 h
at 4°C with the following antibodies: 20gigml-' anti-CD25
and 100gigml ' TU27 for IL-2 binding. After washing, the1048 L. TRENTIN et al.
cells were incubated with PE-IL-2, as reported above. In this
case, the control tube contained IgGl MAb and PE-strep-
tavidin. Ten thousand cells bearing the typical lymphocyte
scatter were scored.
Culture conditions
TIL lines and freshly isolated TILs were cultured in 96
round-bottom well plates (Titretek) in RPMI-1640 medium
supplemented with 10% FCS (ICN), penicillin (50 U ml-')
and streptomycin (50figml-'). Cultures were carried out in
triplicate, with each well containing 1 x 105 cells in 0.2 ml of
medium, and were incubated for 2 days at 37°C in a
humidified atmosphere of 5% carbon dioxide and 95% air.
Recombinant IL-2 was added at the beginning of the culture
at different concentrations (1, 10, 100, 1,000 U ml-'). In
order to block the IL-2-induced effects, the cells were cul-
tured for 30 min with anti-Tac MAb (1:100 final dilution of
ascitic fluid) or TU27 MAb (1:100 final dilution of ascitic
fluid) or control isotype-matched IgG at the beginning of the
culture at 4°C before adding IL-2. The proliferation was
determined by pulsing plates with 1 fiCi per well of [3H]-
thymidine (3H-TdR, CEA Ire Sorin, Saluggia, Italy) for the
last 12h of culture; cells were then harvested and 3H-TdR
incorporation measured in a P-scintillation counter.
Results
Evaluation ofmRNA transcriptsfor IL-2 receptors
To assess the presence of specific mRNA for IL-2 receptors,
Northern blot analysis was performed on six TIL lines. As
shown in Figure 1, all TIL lines tested contained detectable
amounts of p75 mRNA with a size of 4.0 kb. When the same
Northern blot was hybridised with a specific probe for the
p55 IL-2R, p55 mRNA of 3.5 and 1.5 kb was also detected
in all lines. The amount of RNA loaded on the gel is
represented by the constitutionally expressed actin mRNA of
2.1 kb and is reported at the bottom of the figure.
Binding ofanti-IL-2R antibodies and PE-IL-2 to TILs
Flow cytometric analysis showed that both IL-2R subunits
(p55 and p75 chains) were expressed on TIL lines to varying
degrees (p55 IL-2R, 35% ± 8.6; p75 IL-2R, 66% ± 9.3). The
pattern of expression of different receptors in two represen-
tative TIL lines is reported in Figure 2. When the histograms
of TILs stained with anti-p55 and anti-p75 IL-2R MAbs
(Figure 2a and b) were superimposed on the control IgG
histogram, a shift of the two histograms was observed with
respect to the control, thus indicating that the entire popula-
tion of TILs expresses both the p75 and p55 IL-2R, although
to different degrees of density. Blocking experiments of
PE-IL-2 binding with anti-p55 and anti-p75 IL-2R MAbs
were also performed. TILs were treated with these antibodies
either individually or in combination, stained with PE-IL-2
and then analysed by flow cytometry. As illustrated in Figure
2c and d, anti-p55 IL-2R MAb affected the binding of
PE-IL-2 to TILs. A low blocking effect of PE-IL-2 binding
was also observed in the presence of anti-p75 IL-2R MAb.
The analysis of IL-2 receptors on freshly isolated TILs
demonstrated that freshly isolated TILs express both
subunits to a lesser extent (data not shown).
To verify whether some T-cell subsets preferentially bear
the IL-2 receptors, a two-colour analysis was performed
using CD4, CD8 and antil-IL-2R MAbs. The flow cytometric
analysis related to one representative TIL line demonstrated
that both CD4+ and CD8+ cells expressed p55 and p75
IL-2 receptors (Figure 3), and results in other cases were
consistent with this finding.
4 5 6
IL-2R p75 chain
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Figure 1 Northern blot analysis of p75 and p55 IL-2 receptor
expression in total RNA extracted from six TIL lines isolated
(indicated as 1-6). A 10 ig aliquot of total RNA was loaded on
each lane. The amount of loaded total RNA is shown following
hybridisation for actin. The size of the messages is reported in the
Materials and methods section.
Effects ofanti-IL-2R antibodies on in vitro TIL growth
Since anti-p55 IL-2R and anti-p75 IL-2R MAbs have been
shown to bind to TILs, and in order to determine whether
these antibodies affect the biological effects induced by IL-2,
TILs were cultured with different IL-2 concentrations (1, 10,
100, 1,000 U ml-') in the presence or absence of anti-IL-2R
MAbs. Figure 4 shows the mean ± s.d. of 3H-TdR uptake by
12 TIL lines at different IL-2 concentrations. TILs pro-
liferated at both low and high IL-2 concentrations, and these
data are consistent with the phenotypic findings that these
cells are equipped with a high-affinity IL-2R complex. When
TIL lines were cultured in the presence of different concent-
rations of IL-2 and anti-IL-2R MAbs (anti-Tac and TU27
MAbs) (Figure 4), a variable inhibitory effect was observed
when each antibody was individually added to the assay.
When both MAbs were simultaneously added, a complete
block of the IL-2-driven proliferation was observed.
Freshly isolated TILs obtained from four patients were
cultured in the same experimental conditions. The results
obtained in one representative subject are reported in Figure
5. TILs proliferated to low and high concentrations of IL-2
in a way similar to that observed in TIL lines. A variable
inhibitory effect was observed following incubation with anti-
IL-2R MAbs; the proliferation was completely blocked by
the combination of the two MAbs.
Discussion
The data provided herein demonstrate that TILs express both
the p55 and p75 IL-2R subunits and that these structures
deliver a proliferative signal to TILS. In fact, blocking these
receptors resulted in an inhibition of TIL proliferation
induced by IL-2.
The observations that TILs from patients with solid
tumours express both anti-p55 and anti-p75 IL-2R chains
and that specific antibodies inhibit the binding of PE-IL-2
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Figure 2 Immunofluorescent flow cytometric analysis of IL-2 receptors (a and b) and PE-IL-2 binding (c and d) on two
representative TIL lines. The relative cell number is indicated on the ordinate. The histograms of TU27- and CD25-stained cells
were superimposed on the histogram ofcontrol IgG-stained cells (indicated by control). Marker was set up to include >95% of the
control IgG-stained cells. c and d, Effects of pretreatment with anti-CD25 and TU27 MAbs on PE-IL-2-binding. TILs were
pretreated with 20fig ml- anti-CD25 and 1I00 gml1- TU27 before staining with PE-IL-2. Staining with PE-IL-2 alone and with
control IgG plus streptavidin-PE reagent alone is shown.
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Figure 3 Coexpression of p55 IL-2R and p75 IL-2R by CD4 and CD8 T-cell subsets in a representative TIL line.
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Figure 4 Proliferative activity of 12 TIL lines cultured for 72 h
in the presence of different concentrations of IL-2 (1, 10, 100,
1,000 U ml-') with or without different MAbs recognising the
p55 IL-2R (anti-Tac) and the p75 IL-2R (TU27). Cells were
pulsed with 3H-TdR for the last 12 h of the culture. Data are
expressed as mean ± s.d. of the c.p.m. of all TIL lines. LI,
Medium alone; _, IL-2; E, anti-p55 MAb; N, anti-p75
MAb; BE, anti-p55 + anti-p75 MAbs.
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Figure 5 Proliferative activity of freshly isolated TILs obtained
from a patient and cultured for 72 h in the presence of different
concentrations of IL-2 (10, 100, 1,000uml-') with or without
different MAbs recognising the p55 IL-2R (anti-Tac) and the p75
IL-2R (TU27). Cells were pulsed with 3H-TdR for the last 12 h of
the culture. Data are expressed as mean ± s.d. of the c.p.m. of
triplicate experiments. _, IL-2; 1, anti-p55 MAb; 0,
anti-p75 MAb; S1, anti-p55 + anti-p75 MAbs.
indicate that the TIL lines we were dealing with bear both
chains of the IL-2 receptor complex. The evidence that TILs
are equipped with both IL-2R subunits does not directly
mean that these chains contribute to the formation of a fully
functional IL-2R apparatus. In fact, data from the literature
demostrate that the p75 IL-2R chain is able to transduce a
proliferative signal when expressed on lymphoid cells
(Hatakeyama et al., 1989b), while it does not exhibit any
functional activity when expressed on fibroblasts (Hata-
keyama et al., 1989b; Minamoto et al., 1990; Tsudo et al.,
1990). These observations are consistent with the fact that
this subunit does not transduce any signal when expressed
alone on the cell-surface membrane, and suggests that
associated components or modification of the p75 chain are
required in the regulation of binding of IL-2 to this IL-2R
subunit. This hypothesis is further supported by the lack of
any correlation between the number of p75 IL-2R molecules
and the number of IL-2 binding sites on activated cells (Voss
et al., 1990) and by the finding that another molecule of
nearly 64 kDa is likely to represent a prerequisite for the
binding of IL-2 to the p75 IL-2R (Takeshita et al., 1992).
The experiments reported in Figure 4 were designed to
investigate the functional property of these IL-2R molecules
on TIL lines. Our observation that TILs proliferate at low,
intermediate and high IL-2 concentrations and the demons-
tration that anti-IL-2R MAbs (both anti-p55 and anti-p75
IL-2R) inhibit the IL-2-driven TIL proliferation suggest that
a complete and fully functional IL-2 receptor structure is
expressed on TILs grown in vitro. Whether this receptor
apparatus has some clinical relevance in vivo still remains to
be defined. In this regard, the fact that freshly isolated TILs
from four patients were also observed to proliferate in res-
ponse to IL-2 and the demonstration that the proliferative
signal is inhibited by MAbs specifically recognising IL-2
receptors prompts us to speculate that in vivo IL-2 could
preferentially trigger infiltration into the tumour of lym-
phocytes which are equipped with a high-affinity IL-2R. The
triggering of this molecule might result in a cascade of events
(i.e. release of cytotoxic factors, cytokines, etc.) which are
involved in the control of tumour growth in the microen-
vironment where the neoplasia occurs.
Since we provided evidence that both IL-2Rs are expressed
on TILs, the possibility that these receptors are preferentially
expressed on one particular cell subset rather than on
another was ruled out by the analysis of the coexpression of
these structures on CD4 and CD8 subsets. The lack of any
preferential expression of IL-2R on different T-cell subsets
indicates that both CD4 + and CD8 + TILs are charac-
terised by the same receptor structure and suggests that the
IL-2-induced TIL proliferation does not select any discrete
cell subset, at least in terms of expression of CD4 and CD8
molecules.
The possibility that IL-2 receptors might transduce other
functional signals, i.e. the release of cytotoxic factors and
other cytokines which might be involved in the control of
tumour growth and/or outgrowth of TILs themselves, under-
lines the variety of immunoregulatory activities mediated by
these molecules. In this regard tumour necrosis factor a
(TNF-a), a cytokine that is released by TIL following
autologous tumour stimulation (Schwartzentruber et al.,
1991) and following stimulation with IL-2 (Belldegrun et al.,
1989; Wang et al., 1989; Vaccarello et al., 1990; loannides et
al., 1992), might exhibit pleiotropic activites on both TILs
and tumour cells. Studies are in progress to verify this
hypothesis.
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